Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy
Case Report
First Online:
Received:
Accepted:
- 152 Downloads
- 9 Citations
Abstract
We report on a 44-year-old woman affected by dermatopolymyositis resistant to conventional therapies who experienced long-term clinical improvement and remission after treatment with intravenous polyvalent immunoglobulin in a weekly schedule followed by rituximab therapy.
Keywords
Dermatopolymyositis Polyvalent immunoglobulin Anti-CD20 ImmunotherapyNotes
Conflict of interest statement
The authors declare that they have no conflict of interest.
References
- 1.Dalakas MC (1991) Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 325:1487–1498PubMedGoogle Scholar
- 2.Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982. doi: 10.1016/S0140-6736(03)14368-1 CrossRefPubMedGoogle Scholar
- 3.Dalakas MC (2004) Molecular studies in autoimmune inflammatory muscle disorders. Curr Opin Neurol 17:561–567. doi: 10.1097/00019052-200410000-00006 CrossRefPubMedGoogle Scholar
- 4.Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52(2):601–607. doi: 10.1002/art.20849 CrossRefPubMedGoogle Scholar
- 5.Chiappetta N, Steier J, Gruber B (2005) Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 11:264–266. doi: 10.1097/01.rhu.0000182155.08982.60 CrossRefPubMedGoogle Scholar
- 6.Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M et al (2006) Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117(6):1483. doi: 10.1016/j.jaci.2006.04.014 CrossRefGoogle Scholar
- 7.Flores G, Cunningham-Rundles C, Newland AC, Bussel JB (1993) Efficacy of intravenous immunoglobulin in the treatment of autoimmune haemolytic anemia: results in 73 patients. Am J Hematol 44(4):237–242. doi: 10.1002/ajh.2830440404 CrossRefPubMedGoogle Scholar
- 8.Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al (1993) A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000. doi: 10.1056/NEJM199312303292704 CrossRefPubMedGoogle Scholar
- 9.Dalakas MC (2006) The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int Immunopharmacol 6:550–556. doi: 10.1016/j.intimp.2005.11.016 CrossRefPubMedGoogle Scholar
- 10.Umemura T, Kiyosawa K (2006) Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 45:747–748. doi: 10.2169/internalmedicine.45.0158 CrossRefPubMedGoogle Scholar
- 11.Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456–473. doi: 10.1016/j.ctrv.2005.05.007 CrossRefPubMedGoogle Scholar
Copyright information
© Springer-Verlag 2009